Liver disease is showing up more often, and it tracks closely with rising rates of obesity, diabetes, and metabolic syndrome. What many of us trained calling “fatty liver” or NAFLD has been renamed and reframed. The term now is MASLD, metabolic dysfunction-associated steatotic liver disease, and it reflects a better understanding of what actually drives the condition.
Why the change? NAFLD was a definition by exclusion. It told you the disease was not caused by alcohol without saying what it was. It also excluded patients with both alcohol and metabolic drivers, and the word “fatty” carried stigma that most patients felt immediately. In 2023 a multisociety Delphi process involving 236 panelists from 56 countries settled on the new nomenclature. Sixty-six percent of respondents found “fatty” stigmatizing and 61% said the same of “nonalcoholic.” The new definition requires at least one of five cardiometabolic risk factors, and it added MetALD for patients with metabolic dysfunction who also drink significantly (Rinella et al., J Hepatol, 2023).
MASLD is common. Roughly 30% of U.S. adults are affected. Among people with diabetes that figure climbs above 60%, and up to 15% carry advanced fibrosis (Le et al., Clin Mol Hepatol, 2022). Worldwide it is projected to overtake hepatitis C and alcohol as the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplant.
The liver isn’t where most of these patients die. Cardiovascular disease is the leading cause of death in MASLD. The same inflammatory and metabolic pathways that damage the liver drive atherosclerosis. Diabetes worsens MASLD and MASLD worsens diabetes. The relationship runs in both directions.
One point matters more than any other: liver enzymes are a poor marker of severity. Normal ALT and AST are entirely compatible with advanced fibrosis. Fibrosis stage is what predicts progression, complications, and mortality. In a meta-analysis of 4,428 patients, all-cause mortality rose with each fibrosis stage, reaching a relative risk of 3.42 at stage 4 compared with stage 0, and liver-related mortality reached 11.13 (Taylor et al., Gastroenterology, 2020; Ekstedt et al., Hepatology, 2015). That is why guidelines now point everything at fibrosis assessment.
In primary care, FIB-4 is the practical first step. Age, AST, ALT, and platelet count. Under 1.3 suggests low risk and those patients can generally stay in primary care. Above 2.67 means high risk and warrants hepatology referral. Intermediate scores land in a gray zone that usually needs imaging such as FibroScan or a blood-based marker like the ELF test. FibroScan is fast and non-invasive but loses accuracy in patients with obesity, which is a real limitation given who has this disease. MR elastography is the most accurate option and the least available.
Treatment still starts with lifestyle. Weight loss of 5 to 10% improves steatosis and inflammation. The Mediterranean pattern is consistently associated with lower liver fat and better insulin sensitivity. Exercise at 150 minutes a week of moderate activity reduces liver fat even without weight loss, which is worth telling patients who are discouraged by the scale. Cutting sugar-sweetened beverages and limiting fructose is standard advice. Coffee earns its reputation here: a meta-analysis of observational studies found coffee consumption associated with 35% lower odds of significant fibrosis, with three or more cups a day the threshold most often cited, caffeinated or not (Hayat et al., Nutrients, 2021).
Medication options are expanding. Vitamin E has histologic benefit in non-diabetic patients with biopsy-proven MASH, though long-term safety concerns persist. Statins remain badly underused and are safe in MASLD, and they should be prescribed for cardiovascular risk reduction (Kargiotis et al., World J Gastroenterol, 2015). GLP-1 receptor agonists reduce liver fat and support weight loss.
In March 2024, resmetirom became the first FDA-approved drug for MASH with fibrosis. It is a liver-directed thyroid hormone receptor-beta agonist. In the phase 3 MAESTRO-NASH trial, MASH resolution without worsening fibrosis occurred in 25.9% of patients on 80 mg and 29.9% on 100 mg, against 9.7% on placebo, and both doses beat placebo on fibrosis improvement (Harrison et al., NEJM, 2024). It is approved for adults with non-cirrhotic MASH and stage F2 to F3 fibrosis. Those response rates are meaningful and they are also modest, and patients should hear both halves.
Endoscopic and surgical options matter too. Endoscopic sleeve gastroplasty and intragastric balloons reduce liver fat and improve fibrosis. Bariatric surgery remains among the most effective interventions available, with a systematic review and meta-analysis finding NASH resolution in roughly half of patients and fibrosis improvement in about a third (Lee et al., Clin Gastroenterol Hepatol, 2019).
MASLD management has moved well outside hepatology. It needs primary care, cardiology, endocrinology, nutrition, and gastroenterology working the same problem. Screen at-risk patients with FIB-4, particularly those with diabetes or obesity. Counsel on weight and diet. Prescribe statins when indicated. Refer for advanced assessment when fibrosis is suspected.
MASLD reframes liver disease as part of the broader cardiometabolic picture. Treating it means protecting the liver while cutting cardiovascular risk, improving glycemic control, and addressing systemic inflammation. That is where the impact lives.
References:
1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. https://pubmed.ncbi.nlm.nih.gov/37364790/
2. Le MH, et al. Global incidence of non-alcoholic fatty liver disease. Clin Mol Hepatol. 2022;28(4):841-850. https://pubmed.ncbi.nlm.nih.gov/36117442/
3. Taylor RS, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-1625.e12. https://pubmed.ncbi.nlm.nih.gov/32027911/
4. Ekstedt M, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. https://pubmed.ncbi.nlm.nih.gov/25125077/
5. Hayat U, et al. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients. 2021;13(9):3042. https://pubmed.ncbi.nlm.nih.gov/34578919/
6. Kargiotis K, et al. World J Gastroenterol. 2015;21(25):7860-7868.
7. Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. https://pubmed.ncbi.nlm.nih.gov/38324483/
8. Lee Y, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040-1060.e11. https://pubmed.ncbi.nlm.nih.gov/30326299/
Board Certified in Obesity Medicine and Family Medicine
This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.



















